Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a ...

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...

TikTok asks Supreme Court to block ban as Trump warms to it, SoftBank’s promise of 100,000 jobs won’t come easily, and more ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

It’s likely to still be there at the end of the year, but by the time the final sales figures for 2024 are tallied up, Novo ...

President Joe Biden wants Medicare and Medicaid to cover weight-loss drugs, a proposal that would expand access to the costly ...

The obesity treatment market is dominated by Eli Lilly and Novo Nordisk, making it challenging for Viking. Read why I ...

President Joe Biden wants Medicare and Medicaid to cover weight loss drugs, a proposal that would expand access to the costly but life-changing medications for millions of people who struggle with ...

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with obesity-related conditions or take the drugs to become eligible for other ...

Health-care companies fell amid concerns about regulation from the Trump administration. A retreat for UnitedHealth Group continued after President-elect Donald Trump vowed to root "middle men" out of ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. In recent years, these two healthcare leaders have also been butting heads in the GLP-1 weight loss space. Eli Lilly's ...

The FDA is slated to reveal Thursday whether Eli Lilly’s supply of its obesity drug Zepbound can meet U.S. demand. The decision will have major implications both for Lilly and its competitor Novo ...